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Abstract
Purpose:Breast cancer affects both genders, but is understudied
in men. Although still rare, male breast cancer (MBC) is being
diagnosed more frequently. Treatments are wholly informed by
clinical studies conducted in women, based on assumptions that
underlying biology is similar.
Experimental Design: A transcriptomic investigation of male
and female breast cancer was performed, confirming transcrip-
tomic data in silico. Biomarkers were immunohistochemically
assessed in 697 MBCs (n ¼ 477, training; n ¼ 220, validation
set) and quantified in pre- and posttreatment samples from an
MBC patient receiving everolimus and PI3K/mTOR inhibitor.
Results: Gender-specific gene expression patterns were identi-
fied. eIF transcripts were upregulated inMBC. eIF4E and eIF5were
negatively prognostic for overall survival alone (log-rank P ¼
0.013;HR¼ 1.77, 1.12–2.8 and P¼ 0.035;HR¼ 1.68, 1.03–2.74,
respectively), or when coexpressed (P ¼ 0.01; HR ¼ 2.66, 1.26–
5.63), confirmed in the validation set. This remained upon
multivariate Cox regression analysis [eIF4E P ¼ 0.016; HR ¼
2.38 (1.18–4.8), eIF5 P ¼ 0.022; HR ¼ 2.55 (1.14–5.7); coex-
pression P ¼ 0.001; HR ¼ 7.04 (2.22–22.26)]. Marked reduction
in eIF4E and eIF5 expression was seen post BEZ235/everolimus,
with extended survival.
Conclusions: Translational initiation pathway inhibition
could be of clinical utility in MBC patients overexpressing eIF4E
and eIF5. With mTOR inhibitors that target this pathway now in
the clinic, these biomarkers may represent new targets for ther-
apeutic intervention, although further independent validation is
required. Clin Cancer Res; 23(10); 2575–83. 2016 AACR.
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Introduction
The need for more refined therapeutic treatments for male
breast cancer (MBC) is evidenced by a steady stream of publica-
tions highlighting gender-specific differences using IHC (1–5),
genetics (6–11), andmore recently, epigenetics (12–15). Of note,
although MBC is similar histologically to female breast cancer
(FBC), with the same panel of biomarkers used to guide treatment
and prognosis, more rigorous interrogation of the underlying
genetics shows heterogeneity in MBC as recognized in FBC where
molecular profiling has identified different subgroups that cor-
relate with varying clinical outcomes. Gene expression analysis of
MBC is more limited. Nevertheless, genetic disparity has been
reported, notably genes involved in extracellular matrix remodel-
ing, metabolism, and protein synthesis via genes involved in
translational initiation, including eIF4E (10), which are often
upregulated in MBC compared with FBC. Further work has
identified two distinct subgroups of MBC, termed luminal M1
and luminal M2, which differed frommolecular subtypes seen in
FBC (9). This work also reported thatN-acetyltransferase-1, a gene
thought to be involved in drug metabolism, was a prognostic
marker for MBC (9). Subsequent to this, Johansson and collea-
gues documented differential driver genes in MBC versus FBC
(16). Most recently, a distinct repertoire of genetic alterations was
reported in MBC, cautioning the application of FBC data to
therapeutic application in MBC (11). Genomic and immunohis-
tochemical examination of a single MBC patient with recurrent
disease showed a change in hormone receptor expression in the
postprogression sample, with little change at the genomic level,
while receiving a combination of BEZ235/everolimus (17).
Taking advantage of our large collection of MBC samples, we
aimed to generate gene expression profiles of matched MBC and
FBC samples and assess immunohistochemically whether differ-
ences in specific biomarkers affected clinical outcome in men
using a training set of 477anda validation set of 220 cases. Finally,
we analyzed expression of these biomarkers in pre- and posttreat-
ment samples from an MBC patient who received a combination
of the PI3K/mTOR inhibitors BEZ235 and everolimus (17).
Materials and Methods
Ethical approval and patient material
Leeds (East) Research Ethics Committee (06/Q1205/156; 15/
YH/0025) granted ethical approval. For gender comparison tran-
scriptomics, cases were matched for age, size, nodal, and survival
status. Formalin-fixed paraffin-embedded male (n ¼ 15) and
female (n ¼ 10) primary invasive ductal carcinoma [estrogen
receptor (ER) positive, HER2 negative, node negative] were iden-
tified from histopathology archives. An additional 3 male and 3
female frozen cases were used to confirm gene expression. A
training set of 477MBCs represented on tissuemicroarrays (TMA;
n ¼ 446, constructed as described in ref. 1) and 31 full-faced
sections, plus a validation set [220 cases on TMAs (9)], was used in
IHC. Patient characteristics are shown in Table 1. Details on the
datasets used in the explorative and validation phases are pro-
vided (Supplementary Fig. S1). Cases were pseudo-anonymized
and data analyzed anonymously.
Gene expression
Extracts from five 10-mm sections were applied to Almac
Diagnostics Breast Cancer DSA platform representing 21,808
genes, according to in-house protocols (18). Three MBC samples
failed QC and were excluded from further analysis. Genes that
were significantly differentially expressed between genders were
calculated from Almac-normalized and transformed data with
FDR threshold of 5% and a fold change significance of 1%.
Representative heatmaps were generated from resulting expres-
sion data using hierarchical clustering and Pathway Ingenuity
Analysis to identify gender-specific gene expression. The micro-
array data are available on ArrayExpress (www.ebi.ac.uk/arrayex-
press, accession number E-MTAB-4040). TheOncomine platform
was used for further data mining.
IHC
REMARK criteria were employed (19). IHC was conducted as
described previously, using well-validated antibodies (20),
including eIF1 (Abcam; ab118979, 1:200), eIF2 (Abcam;
ab32157, 1:150), eIF3 (Abcam; ab171419, 1:150), eIF4E (Santa
Translational Relevance
Genomic and transcriptomic analysis of four independent
male breast cancer datasets identified upregulation of trans-
lational initiation pathway genes. eIF4E and eIF5 were inde-
pendent predictors of survival, either alone or when coex-
pressed. Samples from a patient receiving a combination of
agents targeting this pathway suggest this pathway may be
tractable.
Table 1. Clinicopathologic data for the MBC training and validation sets
Characteristics Training set Validation set
Mean age (range) 66 (30–97) 70 (23–98)
Mean follow-up, years (range) 3.9 (0.08–24.5) 4.6 (0.04–15)
Treatment Various combinations of adjuvant
hormonal, chemo, and radiotherapy
Histology Number (%) Number (%)
Invasive 419 (88) 130 (59)
DCIS 7 (1) 4 (2)
Mixed 15 (3) 47 (21)
Unknown 36 (8) 39 (18)
Grade
1 50 (10) 15 (7)
2 193 (41) 98 (44)
3 147 (31) 85 (39)
Unknown 87 (18) 22 (10)
Lymph node
þ 134 (28) 78 (35)
 147 (31) 83 (38)
Unknown 196 (41) 59 (27)
ERa
þ 404 (85) 193 (88)
 30 (6) 9 (4)
Unknown 43 (9) 18 (8)
PR
þ 352 (74) 160 (73)
 74 (15) 41 (19)
Unknown 51 (11) 19 (9)
HER2
þ 6 (1)a 18 (8)a
 291 (65 157 (71)
Unknown 149 (34) 45 (20)
Abbreviation: DCIS, ductal carcinoma in situ.
aConfirmed by FISH/CISH.
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Cruz Biotechnology; sc-9976, 1:400), and eIF5 (Abcam; ab32443,
1:300). Cases were batch stained for each antibody with recom-
mended controls. TMAs were digitized (40, Leica-Aperio AT2
ScanScope scanner; Leica Biosystems). Each TMA core was viewed
using in-house software and assessed semiquantitatively for each
biomarker, taking account of staining intensity and percentage of
tumor cells. Overall scores were averaged from either duplicate or
triplicate cores that represented a case. Staining was generally
cytoplasmic; our group has shown that nuclear staining is seen
occasionally but is not of prognostic value (20); therefore, only
cytoplasmic staining was considered. Scoring criteria were deter-
mined from previously reported studies (20, 21). Cases were
scored by MPH with coscoring of 10% (C.A.B. Suleman, trainee
histopathologist), overseen by A.M. Shaaban, specialized breast
consultant histopathologist. Where disagreement was reported
(score >2; n ¼ 5), cases were rereviewed to reach consensus.
Excellent strength of agreement was observed between scorers
using interclass correlation coefficients (eIF1 0.911 [95% confi-
dence interval (CI), 0.769–0.944], eIF2 0.846 (95% CI, 0.736–
0.910), eIF4E0.882 (95%CI, 0.755–0.913), and eIF5 0.865 (95%
CI, 0.769–0.922). Scores were indeterminable in 49 cases due to
core loss/exhaustion during processing, well-recognized with
TMAs.
Analysis of eIF4E and eIF5 on a single patient progression series
treated with PI3K/mTOR inhibitors
Pre- and posttreatment biopsies were obtained from a 66-
year-old Caucasian male diagnosed in 2006 with ERþ, proges-
terone receptor positive (PRþ), HER2 infiltrative papillary
breast cancer whose clinical history has been reported (17).
Following mastectomy, he received adjuvant tamoxifen but
developed a contralateral grade 3 ERþ, PRþ, HER2 infiltrative
ductal carcinoma 2 years later (pretreatment sample). Standard
adjuvant chemotherapy commenced, with 5 weeks of
Figure 1.
Identification of eIF pathway
upregulation in MBC by hierarchical
clustering and validation in an external
dataset. A, Heatmap showing gender-
specific hierarchical clustering of
differentially expressed genes in
female (pink) and male (blue) breast
cancers with exploded view of eIF
genes, which were significantly
overexpressed inMBC on the right (P <
0.0001; eIF pathway genes and P ¼
0.016; FDR). B, Hierarchical clustering
of a reanalysis of the Callari et al.
dataset (10) similarly identified
members of the eIF family were
overexpressed in MBC as shown in the
exploded view on the right. Green,
overexpression; red, underexpression.
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radiotherapy and subsequent adjuvant letrozole. Thirteen
months later, he developed multiple nodal and bilateral lung
metastases and was switched to a schedule of vinorelbine plus
capecitabine every 3 weeks. Following disease stabilization, he
received fulvestrant. After 8 months, node progression was
noted, and the patient was switched to BEZ235 (200 mg orally,
twice daily) plus subtherapeutic everolimus (2.5 mg orally,
weekly). Aside from a skin rash, this was well tolerated, and
stable disease was maintained for a further 18 months after
which a nodal metastasis developed (posttreatment sample).
eIF4E and eIF5 expression was assessed immunohistochemi-
cally in the pre- and posttreatment samples, as described above
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Figure 2.
The effect of eIF expression on DFS and OS in MBC by
Kaplan–Meier survival analysis. A–H, Effects on OS are
shown in A, C, E, and G and DFS in B, D, F, and H. A and
B ¼ eIF1; C and D; eIF2; E and F ¼ eIF4E; and G and
H ¼ eIF5. Gray line, high expression; black line, low
expression, dichotomized by ROC analysis and analyzed
by log-rank test.
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and reviewed by two investigators (M.P. Humphries and A.M.
Shaaban) and quantified (Leica Aperio positive pixel count
algorithm, version 9).
Statistical analysis
ROC curves were generated to obtain relevant cutoffs (22).
Associations with disease-free and overall survival (DFS, from
initial diagnosis to the diagnosis of local or distant recurrence;
OS, from initial diagnosis to death) were analyzed (Kaplan–
Meier plots, log-rank test). HRs were determined by Cox regres-
sion. Follow-up patient information was updated in June 2013
and survival periods calculated. Patients were censored at the
last day they were known to be alive. Variables were entered in
univariate and multivariate analysis (Cox proportional hazards
regression model). Gene expression P values were adjusted for
multiple testing using the FDR method (Benjamini–Hochberg
procedure).
Results
Gender comparison of gene expression
Hierarchical agglomerative clustering revealed differential gene
expression patterns in MBC and FBC (Fig. 1A). Unsupervised
clustering revealed three distinct gender-specific clusters. The top
gene cluster displayed higher expression in MBC. The middle
cluster showed lower expression in MBC, whereas the bottom
cluster was overrepresented in MBC. Further analysis of the top
cluster showed components of the translational initiation
machinery were overexpressed in MBC compared with FBC,
notably genes associated with translational initiation pathway.
This was confirmed throughmining an independentMBC dataset
(Fig. 1B; ref. 10) and also by interrogation of Oncomine, which
showed higher expression of eIF4E and eIF5 in breast and lung
cancer compared with matched normal tissue. When these
biomarkers were compared for gender, eIF4E and eIF5 expression
was proportionately higher in male breast but not lung cancer
(Supplementary Fig. S2).
eIF4E and eIF5 expression are independently prognostic in
MBC
Having identified gender-specific differences in eIF gene expres-
sion, we examined this immunohistochemically in 697 MBCs:
training set (n ¼ 477) and validation set (n ¼ 220; ref. 9).
Cytoplasmic expression was present in invasive tumor cells for
all familymembers examined except eIF3, which was consistently
negative, despite positive staining of colon-positive control tissue
(Supplementary Fig. S3). Training and validation sets were scored
semiquantitatively for eachbiomarker, taking account of intensity
of staining and percentage of positive tumor cells. Representative
staining for each eIF is shown in Supplementary Fig. S3. ROC
curves were plotted and used to determine the optimum cut-off
Table 2. Univariate and multivariate analysis of eIF4E and eIF5 expression in MBC
Univariate analysis (all biomarkers)
Training set Validation set Combined dataset
Variable HR (CI) P HR (CI) P HR (CI) P
Grade 1.590 (1.007–2.511) 0.047 1.116 (0.849–1.466) 0.432 1.252 (1.006–1.557) 0.044
Age 1.055 (1.032–1.079) 0.000002 1.004 (1.002–1.005) 0.000017 1.005 (1.003–1.006) 2.1E10
Size (>20 mm) 1.006 (0.997–1.014) 0.209 1.428 (0.990–2.059) 0.057 1.146 (1.080–2.016) 0.014
Node positivity 1.549 (0.948–2.532) 0.081 1.150 (1.094–1.209) 4.4E09 1.695 (1.252–2.295) 0.001
eIF4E 1.777 (1.128–2.800) 0.013 1.564 (1.028–2.378) 0.037 2.196 (1.634–2.952) 1.4E07
eIF5 1.685 (1.036–2.742) 0.035 1.674 (1.003–2.793) 0.049 1.347 (0.944–1.922) 0.101
Coexpression 2.664 (1.260–5.633) 0.01 2.228 (1.093–4.542) 0.027 2.776 (1.683–4.579) 0.00006
Multivariate analysis (EIF4E)
Training set Validation set Combined dataset
Variable HR (CI) P HR (CI) P HR (CI) P
Grade 1.002 (0.583 1.721) 0.995 1.106 (0.826–1.483) 0.498 1.169 (0.902–1.515) 0.237
Age 1.052 (1.017–1.088) 0.003 1.003 (1.002–1.005) 0.0001 1.004 (1.002–1.006) 0.000005
Size (>20 mm) 1.008 (0.997–1.019) 0.173 1.223 (0.828–1.805) 0.312 1.203 (0.885–1.692) 0.290
Node positivity 1.445 (0.739–2.822) 0.282 1.131 (1.072–1.193) 0.000006 1.621 (1.150–2.286) 0.006
eIF4E 2.380 (1.179–4.805) 0.016 1.333 (0.866–2.052) 0.192 2.297 (1.576–30262) 0.00001
Multivariate analysis (EIF5)
Training set Validation set Combined dataset
Variable HR (CI) P HR (CI) P HR (CI) P
Grade 1.075 (0.606–1.907) 0.805 1.065 (0.787–1.441) 0.683 1.101 (0.843–1.437) 0.482
Age 1.070 (1.033–1.107) 0.0001 1.003 (1.001–1.005) 0.002 1.004 (1.002–1.005) 0.0001
Size (>20 mm) 1.008 (0.997–1.019) 0.138 1.248 (0.833–1.870) 0.282 1.294 (0.922–1.117) 0.136
Node positivity 1.813 (0.911–3.610) 0.09 1.134 (1.073–1.198) 0.000008 1.621 (1.150- 2.286) 0.007
eIF5 2.552 (1.142–5.702) 0.022 1.528 (0.881–2.650) 0.131 2.267 (1.576–3.262) 0.044
Multivariate analysis (coexpression of EIF4E and EIF5)
Training set Validation set Combined dataset
Variable HR (CI) P HR (CI) P HR (CI) P
Grade 0.391 (0.137–1.114) 0.079 1.692 (0.858–3.336) 0.129 0.865 (0.508–1.472) 0.592
Age 1.039 (0.992–1.088) 0.104 1.003 (1.001–1.006) 0.01 1.004 (1.002–1.007) 0.001
Size (>20 mm) 1.008 (0.991–1.026) 0.34 2.530 (1.170–5.472) 0.018 1.869 (1.040–30360) 0.037
Node positivity 2.927 (0.953–8.992) 0.061 1.620 (1.235–2.125) 0.0004 2.580 (1.348–4.937) 0.004
Coexpression 7.037 (2.223–22.269) 0.001 1.650 (0.724–3.757) 0.233 30343 (1.791–6.242) 0.0001
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value for each antibody. These were eIF1, 5.5; eIF2, 4.75; eIF4E,
5.77; and eIF5, 6.41 (Supplementary Fig. S3).
Kaplan–Meier survival curves showing the impact of eIF expres-
sion on OS and DFS are shown (Fig. 2). Expression of eIF4E and
eIF5 was associated with worse OS. This relationship was also
observed in the validation set and remained upon multivariate
analysis in the larger training set when adjusted for age, tumor
size, lymph node positivity, and grade (Table 2), even with
disparity in significance of lymph node status between the two
datasets; we attribute this to differences in the weighting of live/
dead in each dataset. Alternatively, this may reflect the lack of
complete data on lymph node status in both cohorts (Table 1);
despite our best efforts,wewere unable toobtain this. Significance
remained when the training and validation sets were combined
(n ¼ 697 cases; Table 2).
As only eIF4E and eIF5 impacted on survival, we examined the
effects of their coexpression. Low expression was determined for
cases with scores below the defined cut-off point: <5.77 for eIF4E
and <6.41 for eIF5 (n¼ 96). High expression: >5.77 for eIF4E and
>6.41 for eIF5 (n ¼ 14). Cases that overexpressed eIF4E and eIF5
(>5.77, >6.41, respectively) had significantly shorter survival
compared with those who expressed eIF4E and eIF5 at lower
levels (<5.77, <6.41, respectively; Fig. 3). Cases that were high for
one of the proteins fell between both curves (data not shown).
Coexpression of eIF4E and eIF5 remained significant upon mul-
tivariate analysis [P ¼ 0.001; HR, 7.037 (2.223–22.2)] in the
training set (Table 2). Correlations between eIF4E expression
with PR (P < 0.001) and low tumor grade (P < 0.036) were
observed, while AR correlated with eIF5 (P < 0.035), with a trend
toward correlation with PR and low grade (Supplementary Table
S1). No significant correlation with clinicopathologic parameters
was observed in cases that coexpressed eIF4E and eIF5, although
trends with lower grade and PR were suggested.
BEZ235/everolimus combination therapy alters eIF4E and
5 expression
As overexpression of eIF4E and eIF5 was associated with
reduced OS, we examined the effects of treatments known to
impact on their signaling in a single MBC patient. In the pretreat-
ment sample, strong cytoplasmic expression of eIF4E and eIF5
was observed (Fig. 4A and C, respectively). Strikingly in the
posttreatment sample, a marked reduction in staining was
observed for both biomarkers, 89% to 58% (eIF4E), 87% to
35% (eIF5), accompanied by a shift in location of eIF5 from the
cytoplasm to the nucleus (Fig. 4B and D).
Discussion
To our knowledge, this is the largest study in MBC reported
to date, examining more than 700 cases at the transcriptomic
and immunohistochemical levels across four independent
datasets. Key findings were upregulation of genes of the trans-
lational initiation pathway in MBC in two independent tran-
scriptomic screens, followed by identification of eIF4E and eIF5
as independent predictors of survival, either when evaluated
alone or when coexpressed, where there was an even stronger
negative survival influence. We also provide evidence that the
translational initiation pathway may be tractable by studying
samples from an MBC patient who received an investigational
combination of agents that target this pathway, namely BEZ235
and everolimus.
The role of initiation factors in the progression to a malignant
phenotype is reported in many cancers, including, breast, head
and neck, liver, prostate, bladder, gastric, colon, ovarian, glioma,
lymphoma, non–small cell lung carcinoma, cervical, small intes-
tine, and melanoma (20, 23–25). This has highlighted eIFs,
notably eIF4E, as indicative of poor prognosis. Originally shown
to be overexpressed in breast cancer (26), eIF4E is essential for
translation and is a rate-limiting step in RNA recruitment to
ribosomes (27). Indeed, most of the direct inhibitors of the eIF
machinery are targeted toward eIF4E (28).Moreover, eIF4E and its
associated binding proteins have been shown to correlate with
survival duration in FBC, where cases with high expression of
eIF4E relative to its binding proteins had significantly worse
survival (20). Our results corroborate these and other findings
where elevated eIF4E expression predicts poor survival in FBC
(21, 29, 30).
Recently, 337 cases from our 477-case training set were exam-
ined independently, suggesting eIF4E expression had no prog-
nostic effect inMBC (31). This anomalymight be explainedby the
different times used to estimate survival in the two studies. In this
study, survival status was updated in June 2013 (by S. Sundara
Rajan), while survival data in the cases used byMillican-Slater and
colleagues (31) were earlier, 2008 to 2009, and only available for
187 cases. As well as using the most up to date survival informa-
tion available, this emphasizes the need for inclusion of suffi-
ciently large numbers of samples for robust validation studies
when estimating the effects of biomarkers on survival, as widely
discussed (32, 33). The large number of cases in our training
(n ¼ 477) and validation (n ¼ 220) cohorts with follow-up on
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Figure 3.
Coexpression of eIF4E and eIF5 significantly impacts on MBC survival by
Kaplan–Meier survival analysis. Cases that coexpressed eIF4E and eIF5 were
stratified into low (score <5.77, <6.41, respectively; n ¼ 96) or high (score
>5.77, >6.41, respectively; n ¼ 14) expression. Cases that overexpressed
eIF4E and eIF5 had significantly shorter survival compared with those who
expressed eIF4E and eIF5 at lower levels. Gray line, high expression; black line,
lower expression, log-rank test.
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>70% as well as concordance with previous literature (20, 21, 29,
30) are significant strengths, all pointing toward eIF4E being a
poor prognostic factor in breast cancer, irrespective of gender.
Given that we wished to identify potential gender-specific differ-
ences in gene expression in breast cancer, this result may be
perceived as surprising. However, there are multiple examples of
biomarkers being expressed in different, or even the same type, of
breast cancer, but which are only of clinical use when expressed
above a certain threshold (reviewed in ref. 34). Interestingly, a
search on Oncomine showed that eIF4E and eIF5 were not only
increased in tumor versus normal breast and lung cancers, but that
eIF4E and eIF5 expression was proportionately higher in MBC
when genders were compared, substantiating our findings. How-
ever, althoughwehave shown eIF4E and eIF5 are elevated inMBC,
this does not preclude their expression and targeting in FBC. Aswe
move toward personalized medicine, case-specific biomarker
expression and their quantitative expression levels should help
optimize tailored therapies for breast cancer in both genders.
As reported elsewhere (1, 35–37), our MBC cohort was almost
universally ERþ, expressed in >90% of cases. As previous gene
expression profiling studies indicate that MBC shares more fea-
tures with ER FBC than ERþ FBC (9), it is of interest to note that
eIF4E overexpression has also been reported to negatively impact
survival in triple-negative FBC (38). Thus, as well as sharing
genomic similarities, this could indicate that ERþ MBCs share a
prognostic biomarker with ER FBC.
eIF5 is essential in the translation initiation process, responsi-
ble for the association of eIF2 with Met-tRNA (39), yet its precise
role in cancer pathogenesis remains elusive. To our knowledge,
this is the first time it has been shown to negatively affect survival
duration inMBC. Interestingly, chromosome3q26, the gene locus
of eIF5, is amplified in breast cancer cell lines (40). Both eIF4E,
eIF5, and combinations remained significant, remaining upon
multivariate Cox regression analysis; however, this significance
was reduced in our validation set, which we attribute to sample
size, as follow-up length and treatment regimens were similar in
both datasets (Table 1).
Despite detecting eIF3 mRNA in both MBC and FBC by qRT-
PCR (data not shown), we were unable to detect protein expres-
sion by IHC. Expression in our positive control tissue eliminated
the possibility of poor antibody efficacy or influence of other
preanalytic factors. Nevertheless, there is immunohistochemical
evidence that eIF3 expression is decreased in pancreatic cancer
(24, 41). Further evidence from cancer profiling arrays shows
general downregulation of eIF3 in human tumors (24), which
may explain its lack of expression.
The recognized contribution of eIFs to tumorigenesis has led to
their investigation as therapeutically tractable targets, particularly
using antisense approaches or small-molecule inhibitors (42). A
phase I clinical trial showed reduction of eIF4E protein by up to
65% by an antisense oligonucleotide (LY2275796) inmost of the
30 patients tested (43). Other targets of eIFs include PI3K and
mTOR inhibitors. Rapamycin and analogues, upstream signaling
inhibitors of translation initiation, are now in the clinic (44–46).
Weassessed eIF4E and eIF5 expression in anMBCpatientwhowas
treated with agents known to impact these signaling pathways,
namely themTOR inhibitor everolimus (Afinitor/RAD001) given
in combination with BEZ235, an inhibitor of class I PI3K mole-
cules and the mTORC1 and mTORC2 complexes. This clearly
demonstrated a striking reduction in the expression of eIF4E and
eIF5 (>50%) in the posttreatment samples. As the mTORC1/2
pathways are upstream of eIF4E (47), we predict their inhibition
may result in declining levels of eIF proteins. Another study
showed a reduction in eIF4E expression in approximately one
third of breast cancers following treatment with everolimus (48).
As overexpression of both eIF4E and eIF5 was associated with
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eIF5 Pretreatment eIF5 Posreatment
(i) BA (i)
C (i) D (i)
(ii)
(iii)
(ii)
(iii)
(ii)
(iii)
(ii)
(iii)
Posivity = 89%
Posivity = 87%
Posivity = 58%
Posivity = 35 %
Figure 4.
BEZ235/everolimus combination therapy reduces eIF4E and eIF5 expression. A–D, (i) eIF4E and eIF5, expression in BEZ235/everolimus pre- and
posttreatment patient samples, respectively; (ii) exploded views of a higher magnification of eIF4E and eIF5 staining in pre- and posttreatment patient
samples, respectively; (iii) the positive pixel counting analysis images of the eIF4E and eIF5 higher magnification images from pre- and posttreatment
patient samples, respectively. Scales bar (A–D, i), 300 mm; those on higher magnification and positive pixel analysis images ¼ 60 mm.
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worse OS in MBC, it is tempting to speculate that action of the
BEZ235/everolimus combination could deregulate their molec-
ular pathways, resulting in reduction in their expression, leading
to survival benefit, as stable diseasewasmaintained for 18months
after the BEZ235/everolimus switch. However, it is worth noting
that the patient had alreadybeenheavily treatedwithother chemo
and endocrine agents prior to this switch, which may have
contributed to the reduction in eIF4E and eIF5 expression we
report. Nevertheless, this intriguing result is supported by in vivo
animal data in which suppressing mTOR activity and its down-
stream translational regulators delayed breast cancer progression
(49). Clearly, further validation is required. Lack of specific male
breast cancer cell line models, precludes this in vitro; potentially,
this could be considered in the context of MBC-specific clinical
trials, for example, as recommended by the International Male
Breast Cancer Program (50). Another interesting observation was
the relocation of eIF5 from a cytoplasmic to a nuclear location in
the posttreatment sample. As the association of eIF2 with Met-
tRNA by eIF5 occurs in the cytoplasm (39), the biological reasons
for its presence in the nucleus are unknown.
In summary, gene expression analysis revealed that, compared
with FBC, genes involved in the translational initiation pathway
are overexpressed in MBC, corroborated by in silico validation in
an independent dataset and immunohistochemical analysis dem-
onstrating that overexpression of eIF4E and eIF5 are predictive of
reduced patient survival in 697 MBCs with long-term follow-up.
Together with our data on pre- and posttreatment evaluation of
these biomarkers in an MBC patient, our findings suggest that
MBCs that overexpress eIF4E and eIF5 might be considered as
candidates for treatment with agents that target the translation
machinery in cancer. Indeed preclinical data support the use of
inhibition of translation initiation as an emerging new paradigm
in cancer therapy (51).
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